Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy

Experimental and Molecular Medicine

Volumn 43, Issue 10, 2011, Pages 580-586

  Kim, Chae Young ^a,b   Park, Soon Hye ^a   Jeong, Moonsup ^a   Kwon, O Seo ^a   Doh, Hyounmie ^a   Kang, Su Hyung ^a   Robbins, Paul D ^c   Kim, Byong Moon ^a   Seol, Dai Wu ^c,d   Kim, Byung Gee ^b  

^a Dong A Pharmaceutical Company   (South Korea)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Chung Ang University   (South Korea)

Author keywords

Gene therapy; Glioma; Pharmacokinetics; TNF related apoptosis inducing ligand

Indexed keywords

ADENOVIRUS VECTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE THERAPY; GLIOBLASTOMA; GLIOMA; HALF LIFE TIME; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS PARTICLE;

ADENOVIRIDAE; RATTUS;

EID: 80055039138     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2011.43.10.065     Document Type: Article

References (15)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
2. Degli-Esposti M. To die or not to die - the quest of the TRAIL receptors. J Leukoc Biol 1999;65:535-542.
3. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997;71:1842-1849.
4. Hiltunen MO, Turunen MP, Turunen AM, Rissanen TT, Laitinen M, Kosma VM, Ylä-Herttuala S. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000;14:2230-2236.
5. Jeong M, Kwon YS, Park SH, Kim CY, Jeun SS, Song KW, Ko Y, Robbins PD, Billiar TR, Kim BM, Seol DW. Possible novel therapy for malignant glioma with secretable trimeric TRAIL. PLoS One 2009;4:e4545
6. Kang SM, Braat D, Schneider DB, O'Rourke RW, Lin Z, Ascher NL, Dichek DA, Baekkeskov S, Stock PG. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation 2000;69:1813-1817.
7. Kim CY, Jeong M, Muchiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006;4:330-338.
8. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-2422.
9. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. Malignant gliom genetics and biology of a grave matter. Genes Dev 2001;15:1311-1333.
10. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther 2005;16:664-677.
11. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-12690.
12. Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, Mittal SK. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009;386:44-54.
13. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
14. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 1995;21:128-151.
15. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82